Manganese produce a parkinsonism-like illness characterized by movement abnormalities. This condition is not responsive to typical therapies used in the treatment of PD, suggesting an alternative pathway than the typical dopaminergic loss within the substantia nigra. Manganese may accumulate in the basal ganglia, leading to the abnormal movements. A mutation of the SLC30A10 gene, a manganese efflux transporter necessary for decreasing intracellular Mn, has been linked with the development of this Parkinsonism-like disease. The Lewy bodies typical to PD are not seen in Mn-induced parkinsonism. Animal experiments have given the opportunity to examine the consequences of manganese overexposure under controlled conditions.
Manganese dioxide chlorine as a by-product. A third process involves manganese heptoxide and manganese monoxide. The two reagents combine with a 1:3 ratio to form manganese dioxide: Lastly the action of potassium permanganate over manganese sulphate crystals produces the desired oxide. Electrolytic manganese dioxide (EMD) is used in zinc–carbon batteries together with zinc chloride and ammonium chloride. EMD is commonly used in zinc manganese dioxide rechargeable alkaline (Zn RAM) cells also. For these applications, purity is extremely important. EMD is produced in a similar fashion as electrolytic tough pitch (ETP) copper: The manganese dioxide is dissolved in sulfuric acid (sometimes mixed with